Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp68 | Bone development/growth and fracture repair | ECTS2013

Long bone phenotypic analyzes of a RANK transgenic mouse line

Baaroun Vanessa , Coudert Amelie , Marty Caroline , Castaneda Beatriz , Berdal Ariane , Descroix Vianney

Introduction: Bone metastasis pathophysiology is currently defined as a vicious circle. Indeed, tumor cells co-express RANK-L and its receptor, RANK, allowing their own proliferation and peritumoral bone resorption necessary to the lesion expansion. Odontogenic tumors, which occur within the jaw, seem to present the same pathophysiological characteristics. Thus, studying the impact on bone of RANK over-expression by the osteoclasts would permit a better understanding of those ...

ba0001pp400 | Osteoporosis: treatment | ECTS2013

Osteonecrosis of the jaw and non-malignant disease

Coudert Amelie , Lescaille Geraldine , Baaroun Vanessa , Azerad Jean , Cohen-Solal Martine , Berdal Ariane , Descroix Vianney

Bisphosphonates (BP) are powerful bone resorption inhibitors. They are used for the symptomatic treatment of malignant osteolytic bone disease (e.g. multiple myeloma and bone metastasis), as well as bone diseases associated with high bone resorption (e.g. postmenopausal osteoporosis, cortisone-induced osteoporosis). However, recent data showed that a rare, but serious, adverse effect of BP therapy is osteonecrosis of the jaw (BRONJ). Given the increasing number of persons rece...